ESSA Pharma Leadership

David Parkinson is acting CEO of Zyngenia, Inc., and a Venture Partner at New Enterprise Associates (NEA). From 2007 until 2012.Parkinson has served as a director of the Company since June 24, 2015 and has been employed full time as the President and Chief Executive Officer of the Company since January 7, 2016. Parkinson served as President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Prior to 2007, Parkinson was Senior Vice President of Oncology Research and Development at Biogen Idec 2006-2007, Vice President of Oncology Development at Amgen 2003-2006 and Vice President of Global Clinical Oncology Development at Novartis 1997-2003. Parkinson also worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as acting Associate Director of the Cancer Therapy Evaluation Program. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee, has also served on the FDA’s Science Board, and is a recipient of the FDA's Cody Medal. He has served on the National Cancer Policy Forum of the Institute of Medicine, as a board director for the Ontario Institute for Cancer Research, and is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. He currently serves as a Board Director for the Multiple Myeloma Research Foundation and has served as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committee for the last 15 years. Parkinson was formerly a Director of Facet Biotech, Inc. and Ambit Biosciences, both public biopharma companies which were acquired by large pharma. He currently serves as Director on the Boards of Cerulean Pharma Inc., 3S Bio Inc. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications.

David Parkinson is acting CEO of Zyngenia, Inc., and a Venture Partner at New Enterprise Associates (NEA). From 2007 until 2012.Parkinson has served as a director of the Company since June 24, 2015 and has been employed full time as the President and Chief Executive Officer of the Company since January 7, 2016. Parkinson served as President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Prior to 2007, Parkinson was Senior Vice President of Oncology Research and Development at Biogen Idec 2006-2007, Vice President of Oncology Development at Amgen 2003-2006 and Vice President of Global Clinical Oncology Development at Novartis 1997-2003. Parkinson also worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as acting Associate Director of the Cancer Therapy Evaluation Program. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee, has also served on the FDA’s Science Board, and is a recipient of the FDA's Cody Medal. He has served on the National Cancer Policy Forum of the Institute of Medicine, as a board director for the Ontario Institute for Cancer Research, and is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. He currently serves as a Board Director for the Multiple Myeloma Research Foundation and has served as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committee for the last 15 years. Parkinson was formerly a Director of Facet Biotech, Inc. and Ambit Biosciences, both public biopharma companies which were acquired by large pharma. He currently serves as Director on the Boards of Cerulean Pharma Inc., 3S Bio Inc. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications.